<DOC>
	<DOCNO>NCT01535469</DOCNO>
	<brief_summary>This step wedge randomize trial design evaluate implementation cryptococcal antigen ( CRAG ) screen preemptive anti-fungal therapy HIV-infected person enter antiretroviral therapy ( ART ) outpatient treatment Uganda . Those ART eligible CD4≤100 cells/mcL serum/plasma CRAG perform lateral flow assay . Those CRAG-positive asymptomatic treat high dose fluconazole . After 6 month survival retention-in-care compare CRAG+ CRAG negative</brief_summary>
	<brief_title>Operational Research Cryptococcal Antigen Screening</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Cryptococcosis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>HIV1 infection CD4≤100 cells/mcL Cryptococcal antigen ( CRAG ) positive age &gt; 14 year Suspected Cryptococcal meningitis Prior know history cryptococcal meningitis currently receive HIV antiretroviral therapy Allergy azole antifungal medication Persons know serious hepatic comorbidities , transaminitis , clinical jaundice receive fluconazole opinion study investigator . Current known pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>cryptococcal meningitis</keyword>
	<keyword>hiv</keyword>
	<keyword>aid</keyword>
	<keyword>implementation science</keyword>
	<keyword>step wedge design</keyword>
	<keyword>retention-in-care</keyword>
</DOC>